Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipelineis currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

$8.7M

Market Cap • 12/26/2024

2015

(9 years)
Founded

2017

(7 years ago)
IPO

NASDAQ

Listing Exchange
Flag of US

Worcester

Headquarters • Massachusetts